Survival in lymphoma is affected by the type and stage of pathology and varies among patients with different conditions. Patients with Hodgkin’s lymphoma have a relatively good prognosis, with 5-year survival rates ranging from 27.4% to 94.3%, and the overall 5-year survival rates for non-Hodgkin’s lymphoma range from 26% to 73%.
The prognosis of Hodgkin’s lymphoma is usually better than that of non-Hodgkin’s lymphoma, and the 5-year survival rate of early-stage patients (Stage I and II) can reach more than 90% after systemic chemotherapy, and the long-term disease-free survival rate is 50%, while the prognosis of advanced-stage patients is relatively poor, and the 5-year survival rate of Stage IV patients is only 31.9%.
Non-Hodgkin’s lymphoma patients can be divided into four groups according to the prognostic index, in which the 5-year survival rate of patients in the low-risk group is about 73%; the 5-year survival rate of patients in the low-intermediate-risk group is 50%; the 5-year survival rate of patients in the intermediate-risk group is 43%; and the 5-year survival rate of patients in the high-risk group is 26%.
It is recommended that patients go to the hospital as early as possible to clarify their pathological type and tumor stage, and ask professional doctors to evaluate the prognosis and survival and actively carry out treatment to improve the prognosis.